Methods: We enrolled probable CAA patients (Boston Criteria 2.0) and, as control group, age‐matched AD patients without radiological signs of CAA, gathering clinical, neuroimaging and follow up data, together with core CSF biomarkers (Aβ42, Aβ40, pTau181, total‐Tau). Here, MAPT is linked to Alzheimer disease.